Summit Therapeutics Inc(SMMT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 7:49 PM ET (Korea 11/6 09:49)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.07 | Insider Own | 80.92% | Shs Outstand | 799.7M | Perf Week | -12.41% |
| Market Cap | 11.32B | Forward P/E | - | EPS next Y | 0.47% | Insider Trans | 1.23% | Shs Float | 152.2M | Perf Month | -20.95% |
| Enterprise Value | 10.71B | PEG | - | EPS next Q | -0.3 | Inst Own | 17.28% | Short Float | 26.86% | Perf Quarter | 1.65% |
| Income | -0.83B | P/S | - | EPS this Y | 25.77% | Inst Trans | 12.71% | Short Ratio | 6.73 | Perf Half Y | -17.26% |
| Sales | 0.00B | P/B | 20.1 | EPS next 5Y | 15.03% | ROA | -174.46% | Short Interest | 40.90M | Perf YTD | -18.87% |
| Book/sh | 0.71 | P/C | 17.97 | EPS past 3/5Y | -52.45% -13.76% | ROE | -220.01% | 52W High | -51.45% ($29.23) | Perf Year | -21.47% |
| Cash/sh | 0.79 | P/FCF | - | Sales past 3/5Y | - | ROIC | -143.36% | 52W Low | 17.56% ($12.07) | Perf 3Y | 605.97% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 13.96% | Gross Margin | - | Volatility(W/M) | 9.04% 6.15% | Perf 5Y | 151.6% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.08 | Perf 10Y | 18.25% |
| Dividend Ex-Date | - | Quick Ratio | 5.99 | EPS Q/Q | 16.26% | Profit Margin | - | RSI (14) | 41.09 | Recom | 1.62 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.99 | Sales Q/Q | - | SMA20 | -9.23% ($15.63) | Beta | -1.52 | Target Price | $29.76 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/11/4 | SMA50 | -12.44% ($16.21) | Rel Volume | 0.98 | Prev Close | $16.17 |
| Employees | 265 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 7.7% -100% | SMA200 | -12.11% ($16.15) | Avg Volume(3M) | 6.07M | Price | $14.19 |
| IPO | 2015/3/5 | Option/Short | Yes/Yes | Trades | 31056 | Volume | 5,940,195 | Change | -12.24% |
This US biopharmaceutical company is a clinical-stage oncology drug developer focused on dual-antibody drug candidates designed to treat cancers such as lung cancer. Because it has yet to generate meaningful revenue, the company's valuation is driven primarily by the clinical trial results of its key drug candidates.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded about as much as usual. That is 98% of its average volume.
SMMT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +25.8% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +151.6%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #20 of 597 in the industry
Based on market cap of $11B.
TECH#19 Bio-Techne Corp $11B PER 62.7 SMMT#20 Summit Therapeutics Inc $11B PER - 
KYMR#21 Kymera Therapeutics Inc $11B PER - 
BMRN#22 Biomarin Pharmaceutical Inc $11B PER - 
PCVX#23 Vaxcyte Inc $10B PER - 
FAQ
What kind of company is SMMT?
SMMT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SMMT?
The market cap of SMMT is approximately $11.3B, ranking 852 within its sector.
What is the 52-week high and low for SMMT?
SMMT has recorded a 52-week high of $29.23 and a low of $12.07.
